Human Microbiome Market

Human Microbiome Market (Indication - Gastrointestinal and Metabolic Disorders, Women’s Health, Cancer; Technology - 16s rRNA Sequencing, Metagenomic Sequencing; Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Women’s Health, Skin Disorders) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

  • Rep Id : TMRGL3999
  • Published On : May 2018
  • No. of Pages : 176
  • Category : Healthcare

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Human Microbiome Market

4. Market Overview
     4.1. Introduction
            4.1.1. Market Definition
            4.1.2. Industry Developments
     4.2. Market Dynamics
            4.2.1. Drivers
            4.2.2. Restraints
            4.2.3. Opportunity
     4.3. Porters Five Forces Analysis
     4.4. Global Human Microbiome Market Analysis and Forecasts
            4.4.1. Global Human Microbiome Diagnostics Market Analysis and Forecast, 2018–2026
            4.4.2. Global Human Microbiome Therapeutics Market Analysis and Forecast, 2020–2026
     4.5. Global Human Microbiome Market Outlook
     4.6. Human Microbiome Therapeutics: Pipeline Overview
     4.7. Regulatory Scenario
     4.8. Impact of human microbiome therapeutics on current treatment options
     4.9. Key Mergers and Acquisitions

5. Global Human Microbiome Diagnostics Market Analysis and Forecasts, by Indication
     5.1. Key Findings
     5.2. Introduction
     5.3. Market Size (US$ Mn) Forecast, by Indication
            5.3.1. Gastrointestinal and Metabolic Disorders
            5.3.2. Women’s Health
            5.3.3. Cancer
            5.3.4. Others
     5.4. Market Attractiveness Analysis, by Indication, 2018
     5.5. Key Trends

6. Global Human Microbiome Diagnostics Market Analysis and Forecasts, by Technology
     6.1. Introduction
     6.2. Market Size (US$ Mn) Forecast, by Technology
            6.2.1. 16s rRNA Sequencing
            6.2.2. Metagenomic Sequencing
     6.3. Market Attractiveness Analysis, by Technology, 2018
     6.4. Key Developments

7. Global Human Microbiome Therapeutics Market Analysis and Forecasts, by Therapeutic Area
     7.1. Key Findings
     7.2. Introduction
     7.3. Market Size (US$ Mn) Forecast, by Therapeutic Area
            7.3.1. Gastrointestinal Disorders
            7.3.2. Metabolic Disorders
            7.3.3. Women’s Health
            7.3.4. Skin Disorders
            7.3.5. Others
     7.4. Market Attractiveness Analysis, by Therapeutic Area, 2020
     7.5. Key Trends

8. Global Human Microbiome Market Analysis and Forecasts, by Region
     8.1. Introduction
     8.2. Market Size (US$ Mn) Forecast, by Region
            8.2.1. North America
            8.2.2. Europe
            8.2.3. Asia Pacific
            8.2.4. Latin America
            8.2.5. Middle East & Africa
     8.3. Market Attractiveness Analysis, by Region,
            8.3.1. Global Human Microbiome Diagnostics Market (2018)
            8.3.2. Global Human Microbiome Therapeutics Market (2020)

9. North America Human Microbiome Market Analysis and Forecast
     9.1. Introduction
     9.2. Market Size (US$ Mn) Forecast, by Indication
            9.2.1. Gastrointestinal and Metabolic Disorders
            9.2.2. Women’s Health
            9.2.3. Cancer
            9.2.4. Others
     9.3. Market Size (US$ Mn) Forecast, by Technology
            9.3.1. 16s rRNA Sequencing
            9.3.2. Metagenomic Sequencing
     9.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
            9.4.1. Gastrointestinal Disorders
            9.4.2. Metabolic Disorders
            9.4.3. Women’s Health
            9.4.4. Skin Disorders
            9.4.5. Others
     9.5. Market Size (US$ Mn) Forecast, by Country
            9.5.1. U.S.
            9.5.2. Canada
     9.6. Market Attractiveness Analysis, by Indication, 2018
     9.7. Market Attractiveness Analysis, by Technology, 2018
     9.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
     9.9. Key Trends

10. Europe Human Microbiome Market Analysis and Forecast
     10.1. Introduction
     10.2. Market Size (US$ Mn) Forecast, by Indication
            10.2.1. Gastrointestinal and Metabolic Disorders
            10.2.2. Women’s Health
            10.2.3. Cancer
            10.2.4. Others
     10.3. Market Size (US$ Mn) Forecast, by Technology
            10.3.1. 16s rRNA Sequencing
            10.3.2. Metagenomic Sequencing
     10.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
            10.4.1. Gastrointestinal Disorders
            10.4.2. Metabolic Disorders
            10.4.3. Women’s Health
            10.4.4. Skin Disorders
            10.4.5. Others
     10.5. Market Size (US$ Mn) Forecast, by Country
            10.5.1. U.K.
            10.5.2. Germany
            10.5.3. Rest of Europe
     10.6. Market Attractiveness Analysis, by Indication, 2018
     10.7. Market Attractiveness Analysis, by Technology, 2018
     10.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
     10.9. Key Trends

11. Asia Pacific Human Microbiome Market Analysis and Forecast
     11.1. Introduction
     11.2. Market Size (US$ Mn) Forecast, by Indication
            11.2.1. Gastrointestinal and Metabolic Disorders
            11.2.2. Women’s Health
            11.2.3. Cancer
            11.2.4. Others
     11.3. Market Size (US$ Mn) Forecast, by Technology
            11.3.1. 16s rRNA Sequencing
            11.3.2. Metagenomic Sequencing
     11.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
            11.4.1. Gastrointestinal Disorders
            11.4.2. Metabolic Disorders
            11.4.3. Women’s Health
            11.4.4. Skin Disorders
            11.4.5. Others
     11.5. Market Size (US$ Mn) Forecast, by Country
            11.5.1. China
            11.5.2. Japan
            11.5.3. Rest of Asia Pacific
     11.6. Market Attractiveness Analysis, by Indication, 2018
     11.7. Market Attractiveness Analysis, by Technology, 2018
     11.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
     11.9. Key Trends

12. Latin America Human Microbiome Market Analysis and Forecast
     12.1. Introduction
     12.2. Market Size (US$ Mn) Forecast, by Indication
            12.2.1. Gastrointestinal and Metabolic Disorders
            12.2.2. Women’s Health
            12.2.3. Cancer
            12.2.4. Others
     12.3. Market Size (US$ Mn) Forecast, by Technology
            12.3.1. 16s rRNA Sequencing
            12.3.2. Metagenomic Sequencing
     12.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
            12.4.1. Gastrointestinal Disorders
            12.4.2. Metabolic Disorders
            12.4.3. Women’s Health
            12.4.4. Skin Disorders
            12.4.5. Others
     12.5. Market Size (US$ Mn) Forecast, by Country
            12.5.1. Brazil
            12.5.2. Mexico
            12.5.3. Rest of Latin America
     12.6. Market Attractiveness Analysis, by Indication, 2018
     12.7. Market Attractiveness Analysis, by Technology, 2018
     12.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
     12.9. Key Trends

13. Middle East & Africa Human Microbiome Market Analysis and Forecast
     13.1. Introduction
     13.2. Market Size (US$ Mn) Forecast, by Indication
            13.2.1. Gastrointestinal and Metabolic Disorders
            13.2.2. Women’s Health
            13.2.3. Cancer
            13.2.4. Others
     13.3. Market Size (US$ Mn) Forecast, by Technology
            13.3.1. 16s rRNA Sequencing
            13.3.2. Metagenomic Sequencing
     13.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
            13.4.1. Gastrointestinal Disorders
            13.4.2. Metabolic Disorders
            13.4.3. Women’s Health
            13.4.4. Skin Disorders
            13.4.5. Others
     13.5. Market Size (US$ Mn) Forecast, by Country
            13.5.1. UAE
            13.5.2. South Africa
            13.5.3. Rest of Middle East & Africa
     13.6. Market Attractiveness Analysis, by Indication, 2018
     13.7. Market Attractiveness Analysis, by Technology, 2018
     13.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
     13.9. Key Trends

14. Competition Landscape
     14.1. Company Profiles
            14.1.1. AO Biome LLC
                     14.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.1.1.2. Recent Developments
                     14.1.1.3. Product Portfolio
                     14.1.1.4. SWOT Analysis
                     14.1.1.5. Strategic Overview
            14.1.2. Enterome Biosciences SA
                     14.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                     14.1.2.2. Product Portfolio
                     14.1.2.3. SWOT Analysis
                     14.1.2.4. Strategic Overview
            14.1.3. Metabiomics Corp.
                     14.1.3.1. Company Overview (HQ, business segments, employee strength)
                     14.1.3.2. Product Portfolio
                     14.1.3.3. SWOT Analysis
                     14.1.3.4. Recent Developments
                     14.1.3.5. Strategic Overview
            14.1.4. MicroBiome Therapeutics LLC
                     14.1.4.1. Company Overview (HQ, business segments, employee strength)
                     14.1.4.2. Product Portfolio
                     14.1.4.3. SWOT Analysis
                     14.1.4.4. Strategic Overview
                     14.1.4.5. Recent Developments
            14.1.5. Osel, Inc.
                     14.1.5.1. Company Overview (HQ, business segments, employee strength)
                     14.1.5.2. Clinical Trial Candidates
                     14.1.5.3. Product Portfolio
                     14.1.5.4. SWOT Analysis
                     14.1.5.5. Strategic Overview
            14.1.6. Rebiotix, Inc.
                     14.1.6.1. Company Overview (HQ, business segments, employee strength)
                     14.1.6.2. Product Portfolio
                     14.1.6.3. SWOT Analysis
                     14.1.6.4. Recent Developments
                     14.1.6.5. Strategic Overview
            14.1.7. uBiome, Inc.
                     14.1.7.1. Company Overview (HQ, business segments, employee strength)
                     14.1.7.2. Recent Developments
                     14.1.7.3. Product Portfolio
                     14.1.7.4. SWOT Analysis
                     14.1.7.5. Strategic Overview
            14.1.8. Second Genome
                     14.1.8.1. Company Overview (HQ, business segments, employee strength)
                     14.1.8.2. Financial Overview: Funding and Investments
                     14.1.8.3. Product Portfolio
                     14.1.8.4. SWOT Analysis
                     14.1.8.5. Strategic Overview
            14.1.9. Seres Therapeutics
                     14.1.9.1. Company Overview (HQ, business segments, employee strength)
                     14.1.9.2. Product Portfolio
                     14.1.9.3. Financial Overview
                     14.1.9.4.  SWOT Analysis
                     14.1.9.5. Strategic Overview
            14.1.10. Synthetic Biologics, Inc.
                     14.1.10.1. Company Overview (HQ, business segments, employee strength)
                     14.1.10.2. Product Portfolio
                     14.1.10.3. Financial Overview
                     14.1.10.4. SWOT Analysis
                     14.1.10.5. Strategic Overview
            14.1.11. Vedanta Biosciences
                     14.1.11.1. Company Overview (HQ, business segments, employee strength)
                     14.1.11.2. Product Portfolio
                     14.1.11.3. Recent Developments
                     14.1.11.4. SWOT Analysis
                     14.1.11.5. Strategic Overview
            14.1.12. Others
                     14.1.12.1. Metabogen AB
                     14.1.12.2. Becton Dickinson & Company
                     14.1.12.3. Evelo Biosciences
                     14.1.12.4. ARTPred
                     14.1.12.5. MaaT Pharma
                     14.1.12.6. Blue Turtle Bio Technologies
                     14.1.12.7. Axial Therapeutics
                     14.1.12.8. Whole Biome
                     14.1.12.9. 4D Pharma
                     14.1.12.10. Symbiotix Therapies
                     14.1.12.11. Phi Therapeutics
                     14.1.12.12. Synlogic
                     14.1.12.13. Biospherex LLC

List of Tables

Table 1: Key Mergers and Acquisitions
Table 2: Global Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 3: Global Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Technology, 2018–2026
Table 4: Global Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2026
Table 5: Global Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Region
Table 6: Global Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Region
Table 7: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 8: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Technology, 2018–2026
Table 9: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Country, 2018–2026
Table 10: North America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2026
Table 11: North America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020–2026
Table 12: Europe Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 13: Europe Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Technology, 2018–2026
Table 14: Europe Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Country, 2018–2026
Table 15: Europe Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2026
Table 16: Europe Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020–2026
Table 17: Asia Pacific Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 18: Asia Pacific Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Technology, 2018–2026
Table 19: Asia Pacific Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Country, 2018–2026
Table 20: Asia Pacific Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2026
Table 21: Asia Pacific Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020–2026
Table 22: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 23: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Technology, 2018–2026
Table 24: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Country, 2018–2026
Table 25: Latin America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2026
Table 26: Latin America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020–2026
Table 27: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 28: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Technology, 2018–2026
Table 29: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Country, 2018–2026
Table 30: Middle East & Africa Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2026
Table 31: Middle East & Africa Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020–2026

List of Figures

Figure 1: Global Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2018–2026
Figure 2: Global Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2020–2026
Figure 3: Human Microbiome Diagnostic Market Value Share by Indication (2018)
Figure 4: Human Microbiome Diagnostic Market Value Share by Technology (2018)
Figure 5: Human Microbiome Therapeutics Market Value Share by Therapeutic Area (2020)
Figure 6: Human Microbiome Therapeutics Market Value Share by Region (2020)
Figure 7: Global Human Microbiome Diagnostic Market Value Share Analysis, by Indication, 2018 and 2026
Figure 8: Global GI & Metabolic Disorders Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 9: Global Women’s Health Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 10: Global Cancer Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 11: Global Others Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 12: Global Human Microbiome Diagnostic Market Attractiveness Analysis, by Indication, 2018
Figure 13: Global Human Microbiome Diagnostic Market Value Share Analysis, by Technology, 2018 and 2026
Figure 14: Global Human Microbiome Diagnostic Market Attractiveness Analysis, by Technology, 2018
Figure 15: Global Metagenomic Sequencing Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 16: Global 16s rRNA Sequencing Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 17: Global Human Microbiome Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2026
Figure 18: Global GI Disorders Market Size (US$ Mn) and Y-o-Y Growth (%), 2020–2026
Figure 19: Global Metabolic Disorders Market Size (US$ Mn) and Y-o-Y Growth (%), 2020–2026
Figure 20: Global Women’s Health Market Size (US$ Mn) and Y-o-Y Growth (%), 2020–2026
Figure 21: Global Skin Disorders Market Size (US$ Mn) and Y-o-Y Growth (%), 2020–2026
Figure 22: Global Others Market Size (US$ Mn) and Y-o-Y Growth (%), 2020–2026
Figure 23: Global Human Microbiome Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020
Figure 24: Global Human Microbiome Diagnostics Market Value Share Analysis, by Region, 2018 and 2026
Figure 25: Global Human Microbiome Therapeutics Market Value Share Analysis, by Region, 2020 and 2026
Figure 26: Global Human Microbiome Diagnostics Market Attractiveness Analysis, by Region, 2018
Figure 27: Global Human Microbiome Therapeutics Market Attractiveness Analysis, by Region, 2020
Figure 28: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2018–2026
Figure 29: North America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2020–2026
Figure 30: North America Diagnostics Market Attractiveness Analysis, by Country, 2018
Figure 31: North America Therapeutics Market Attractiveness Analysis, by Country, 2020
Figure 32: North America Diagnostic Market Value Share Analysis, by Indication, 2018 and 2026
Figure 33: North America Diagnostic Market Value Share Analysis, by Technology, 2018 and 2026
Figure 34: North America Diagnostic Market Value Share Analysis, by Country, 2018 and 2026
Figure 35: North America Therapeutics Market Value Share Analysis by Therapeutic Area, 2020 and 2026
Figure 36: North America Therapeutics Market Value Share Analysis by Country, 2020 and 2026
Figure 37: North America Diagnostics Market Attractiveness Analysis, by Indication, 2018
Figure 38: North America Diagnostics Market Attractiveness Analysis, by Technology, 2018
Figure 39: North America Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020
Figure 40: Europe Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2018–2026
Figure 41: Europe Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2020–2026
Figure 42: Europe Diagnostics Market Attractiveness Analysis, by Country, 2018
Figure 43: Europe Therapeutics Market Attractiveness Analysis, by Country, 2020
Figure 44: Europe Diagnostic Market Value Share Analysis, by Indication, 2018 and 2026
Figure 45: Europe Diagnostic Market Value Share Analysis, by Technology, 2018 and 2026
Figure 46: Europe Diagnostic Market Value Share Analysis, by Country, 2018 and 2026
Figure 47: Europe Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2026
Figure 48: Europe Therapeutics Market Value Share Analysis, by Country, 2020 and 2026
Figure 49: Europe Diagnostics Market Attractiveness Analysis, by Indication, 2018
Figure 50: Europe Diagnostics Market Attractiveness Analysis, by Technology, 2018
Figure 51: Europe Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020
Figure 52: Asia Pacific Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2018–2026
Figure 53: Asia Pacific Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2020–2026
Figure 54: Asia Pacific Diagnostics Market Attractiveness Analysis, by Country
Figure 55: Asia Pacific Therapeutics Market Attractiveness Analysis, by Country
Figure 56: Asia Pacific Diagnostic Market Value Share Analysis, by Indication, 2018 and 2026
Figure 57: Asia Pacific Diagnostic Market Value Share Analysis, by Technology, 2018 and 2026
Figure 58: Asia Pacific Diagnostic Market Value Share Analysis, by Country, 2018 and 2026
Figure 59: Asia Pacific Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2026
Figure 60: Asia Pacific Therapeutics Market Value Share Analysis, by Country, 2020 and 2026
Figure 61: Asia Pacific Diagnostics Market Attractiveness Analysis, by Indication, 2018
Figure 62: Asia Pacific Diagnostics Market Attractiveness Analysis, by Technology, 2018
Figure 63: Asia Pacific Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020
Figure 64: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2018–2026
Figure 65: Latin America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2020–2026
Figure 66: Latin America Diagnostics Market Attractiveness Analysis, by Country, 2018
Figure 67: Latin America Therapeutics Market Attractiveness Analysis, by Country, 2020
Figure 68: Latin America Diagnostics Market Value Share Analysis, by Indication, 2018 and 2026
Figure 69: Latin America Diagnostics Market Value Share Analysis, by Technology, 2018 and 2026
Figure 70: Latin America Diagnostics Market Value Share Analysis, by Country, 2018 and 2026
Figure 71: Latin America Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2026
Figure 72: Latin America Therapeutics Market Value Share Analysis, by Country, 2020 and 2026
Figure 73: Latin America Diagnostics Market Attractiveness Analysis, by Indication, 2018
Figure 74: Latin America Diagnostics Market Attractiveness Analysis, by Technology, 2018
Figure 75: Latin America Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020
Figure 76: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2018–2026
Figure 77: Middle East & Africa Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2020–2026
Figure 78: Middle East & Africa Diagnostics Market Attractiveness Analysis, by Country, 2018
Figure 79: Middle East & Africa Therapeutics Market Attractiveness Analysis, by Country, 2020
Figure 80: Middle East & Africa Diagnostics Market Value Share Analysis, by Indication, 2018 and 2026
Figure 81: Middle East & Africa Diagnostics Market Value Share Analysis, by Technology, 2018 and 2026
Figure 82: Middle East & Africa Diagnostics Market Value Share Analysis, by Country, 2018 and 2026
Figure 83: Middle East & Africa Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2026
Figure 84: Middle East & Africa Therapeutics Market Value Share Analysis, by Country, 2020 and 2026
Figure 85: MEA Diagnostics Market Attractiveness Analysis, by Indication, 2018
Figure 86: MEA Diagnostics Market Attractiveness Analysis, by Technology, 2018
Figure 87: MEA Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020